Keyphrases
Atrial Fibrillation
83%
Anticoagulants
74%
Non-valvular Atrial Fibrillation
45%
New-onset Atrial Fibrillation
42%
Vitamin K Antagonists
41%
Systemic Embolism
35%
Newly Diagnosed
29%
Fibrillation
26%
1-year Outcome
26%
Stroke Prevention
26%
Stroke Risk
25%
Major Bleeding
24%
GARFIELD
23%
All-cause Mortality
21%
Antithrombotic Therapy
21%
Anticoagulation
20%
Antiplatelet
19%
Risk Profile
18%
Treatment Patterns
18%
Non-vitamin K Antagonist Oral Anticoagulants
17%
Therapeutic Range
16%
Bleeding
16%
GARFIELD-AF
16%
2-year Outcome
15%
Africa
15%
Black African
15%
Warfarin
15%
Confidence Interval
14%
High Risk
14%
Hypertension
14%
Antiplatelet Monotherapy
14%
International Normalized Ratio
12%
Anticoagulant Therapy
12%
Baseline Characteristics
12%
Anticoagulant Treatment
11%
Chronic Kidney Disease
11%
Patient Management
10%
Anticoagulant Use
10%
Mortality Factors
10%
Vascular Disease
10%
Hypertension Guidelines
9%
South Africa
9%
Antiplatelet Therapy
9%
Registry Data
8%
Moderate to Severe
8%
Black South African Patients
8%
Systolic Blood Pressure
8%
Low Risk
8%
Diabetes
8%
CHA2DS2-VASc
8%
Event Rate
8%
Sub-Saharan Africa
8%
Clopidogrel
7%
Kidney Disease Progression
7%
Multicenter Trial
7%
Blood Pressure Lowering
7%
Contemporary Perspective
7%
Dosing Algorithm
7%
Warfarin Pharmacogenetics
7%
Latin American Countries
7%
Comprehensive Management
7%
Cardioversion
7%
Supratherapeutic INR
7%
Mechanical Heart Valve Prostheses
7%
INR Control
7%
Self-competence
7%
Generalist
7%
Electrocardiogram Interpretation
7%
Self-rating
7%
Rheumatic Heart Disease
7%
Mortality Prediction
7%
Tuberculous Pericarditis
7%
Patient Characteristics
7%
Oral Anticoagulation
7%
Combination Therapy
7%
Genetic Variants
7%
Risk Stratification
7%
Germany
7%
Pharmacokinetics
7%
Heart Failure with Preserved Ejection Fraction (HFpEF)
7%
Initial Management
7%
Clinical Characteristics
7%
Global Perspective
7%
Austria
7%
Academic Hospital
7%
Addis Ababa
7%
Genetic Markers
7%
AIDS/HIV
7%
Aspirin
7%
Pericarditis
7%
CYP2C9
7%
India
7%
Switzerland
7%
Risk of Death
7%
Prothrombin Time-international Normalized Ratio
6%
Stroke Risk Factors
6%
Hemorrhagic Stroke
6%
CHA2DS2-VASc Score
6%
Congestive Heart Failure
5%
C-statistic
5%
Medicine and Dentistry
Atrial Fibrillation
100%
Apoplexy
62%
Antithrombotic
50%
Vitamin K Antagonist
39%
Antiplatelet
30%
Fibrillation
25%
Anticoagulation
23%
Major Bleeding
17%
All Cause Mortality
16%
Congestive Heart Failure
15%
Anticoagulant Therapy
13%
Monotherapy
12%
Chronic Kidney Disease
10%
Observational Study
9%
Antithrombotic Therapy
9%
Ciclonicate
9%
Anticoagulant
8%
CHA2DS2-VASc Score
8%
Diabetic Hypertension
7%
Cardioversion
7%
Heart Valve Prosthesis
7%
Warfarin
7%
Mechanical Heart Valve
7%
Tuberculous Pericarditis
7%
Randomized Controlled Trial
7%
Ejection Fraction
7%
Risk Stratification
7%
Retrospective Study
7%
Electrocardiogram
7%
Diabetes Mellitus
7%
Systolic Blood Pressure
7%
Blood Pressure
7%
Human Immunodeficiency Virus
7%
Antihypertensive Agent
7%
Pericarditis
7%
Self Concept
7%
Rheumatic Heart Disease
7%
Vascular Disease
7%
Prothrombin Time
6%
Diabetes
6%